Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 118 |
| Active Pipeline (Recruiting Now) | 71 (46) |
| Completed vs Stopped Early | 22 / 24 (20.3%) |
| Median Closed Actual Enrollment | 29 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| UCLA Health and Jonsson Comprehensive Cancer Center | Los Angeles, CA | 94 |
| UC Davis Comprehensive Cancer Center | Sacramento, CA | 6 |
| UC San Diego Health and Moores Cancer Center | San Diego, CA | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04741646 | Ferric Citrate and Chronic Kidney Disease in Children | Phase II | RECRUITING |
| NCT05595499 | Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors | Phase II | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for UCLA Health across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the UCLA Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.